Cuoretech Pty Ltd develops software for the analysis of electrical signals measured from the heart. This involves applying signal processing technology to unravel complex electrical behaviour. Our customers are the leading cardiologists and researchers investigating cures for abnormal heart rhythms. Our flagship product is CEPAS (Cardiac ElectroPhysiology Analysis System) that has been the result of development over several years. It can be used for both real time and offline analysis. We typically customise it to suit specific user needs and to interface to specific hospital laboratory hardware. Atrial Fibrillation is a commonly occurring arrhythmia that is currently the focus of much research. CEPAS has implemented many tools used to analyse fibrillatory signals. Recently Phase Mapping, a technique that has been used to detect rotors causing Atrial Fibrillation, has been implemented.
| Website | http://www.cepas.com.au |
| Revenue | $4 million |
| Employees | 2 (0 on RocketReach) |
| Founded | 2004 |
| Address | Level 1, 3 Innovation Rd, Macquarie University, New South Wales 2109, AU |
| Industry | Medical Equipment Manufacturing |
| Keywords | Cardiology Software, Patient Monitoring Software, Ecg Analysis Software, Remote Patient Monitoring, Digital Health Technology, Heart Rhythm Analysis, Clinical Decision Support, Signal Processing Algorithms, Biomedical Signal Processing, Diagnostic Software, Healthcare It Solutions, Ehealth Solutions, Medical Device Software, Medical Data Analysis, Health Analytics Software |
Looking for a particular Cuoretech employee's phone or email?
Cuoretech Questions
The Cuoretech annual revenue was $4 million in 2026.
Cuoretech is based in Macquarie University, New South Wales.
